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The mechanisms by which CRH and related peptides (i.e. the
CRH/urocortin system) exert their control over thermogene-
sis and weight regulation have until now focused only upon
their effects on brain centers controlling sympathetic out-
flow. Using a method that involves repeated oxygen uptake
determinations in intact mouse skeletal muscle, we report
here that CRH can act directly on skeletalmuscle to stimulate
thermogenesis, an effect that ismore pronounced in oxidative
than in glycolytic muscles and that can be inhibited by a se-
lective CRH-R2 antagonist or blunted by a nonselective CRH
receptor antagonist. This thermogenic effect of CRH can also
be blocked by interference along pathways of de novo lipo-
genesis and lipid oxidation, as well as by inhibitors of phos-
phatidylinositol 3-kinase or AMP-activated protein kinase.
Taken together, these studies demonstrate that CRH can di-
rectly stimulate thermogenesis in skeletal muscle, and in ad-
dition raise the possibility that this thermogenic effect, which
requires both phosphatidylinositol 3-kinase and AMP-acti-
vated protein kinase signaling, might occur via substrate cy-
cling between de novo lipogenesis and lipid oxidation. The
effect of CRH in directly stimulating thermogenesis in skel-
etal muscle underscores a potentially important peripheral
role for the CRH/urocortin system in the control of thermo-
genesis in this tissue, in its protection against excessive in-
tramyocellular lipid storage, and hence against skeletal mus-
cle lipotoxicity and insulin resistance. (Endocrinology 147:
31–38, 2006)
THE CRH SYSTEM consists of distinct populations ofCRH-expressing neurons, a CRH-binding protein, a
family of receptors encoded by two different genes (crhr-1
and crhr-2) with several splice variants, and several related
peptides (urocortin, urocortin 2, and urocortin 3), which are
also ligands for CRH receptors. These components of the
CRH system constitute an elaborate network of neuronal
pathways that play a pivotal role in orchestrating the body’s
overall response to stress and to stress-induced activation of
the hypothalamic-pituitary-adrenal axis (1). TheCRHsystem
also interacts with brain circuitries controlling food intake
and thermogenesis (2). Its role in weight regulation has been
linked to its interaction with peripheral hormonal signals
that inform the brain about the status of the body’s fat re-
serves (2). In particular, the importance of the CRH system
as a target for the anorectic and thermogenic effects of the
adipocyte-secreted hormone leptin has been emphasized in
studies demonstrating that 1) leptin down-regulates the ex-
pression of hypothalamic CRH (3), thereby reducing the
hypothalamic pituitary-adrenal axis activity, and 2) when
administered centrally, CRH antagonists prevent the ano-
rectic effects of leptin (4), whereas CRH, like leptin (5–7),
stimulates whole-body oxygen consumption (8) and sym-
pathetically mediated thermogenesis in brown adipose tis-
sue (9, 10).
Leptin also exerts direct peripheral effects on skeletal mus-
clemetabolism, namely by stimulating glucose use in a phos-
phatidylinositol 3-kinase (PI3K)-dependent manner (11) or
fatty acid oxidation through activation of the AMP-activated
protein kinase (AMPK) and ACC [acetyl coenzyme A (CoA)
carboxylase] axis (12). More recently, leptin has also been
shown to have direct effects on skeletal muscle thermogen-
esis (13), through mechanisms that involve substrate cycling
between de novo lipogenesis and lipid oxidation (14, 15). Such
an energy-dissipating pathway might not only contribute to
the stimulatory effect of leptin replacement on energy ex-
penditure after weight loss (16, 17) but may also be the
mechanism by which leptin regulates intramyocellular lipid
stores and protects skeletal muscle against lipid-induced
stress (lipotoxicity) (18). Whether, as a circulating hormone,
CRH might play similar roles at the periphery is not known.
We therefore decided to test the hypothesis that CRH, like
leptin, may also directly stimulate thermogenesis in skeletal
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muscle on the basis of the following: 1) a splice variant of the
CRH receptor encoded by the crhr-2 gene (CRH-R2) is also
expressed in skeletal muscle (19, 20), and 2) peripheral in-
fusion of CRH stimulates thermogenesis and fat oxidation in
humanswithout signs of increased adipose tissue lipolysis or
activation of the sympatho-adrenal system (21).
To this end, we have evaluated the direct effect of CRH on
skeletal muscle thermogenesis by assessing changes in the
respiration rate of intact murine skeletal muscle (ex vivo) by
a method that involves repeated oxygen uptake determina-
tions for several hours in indirect microcalorimeter cham-
bers. We subsequently examined the extent to which the
thermogenic response to CRH might be altered by selective
inhibitors of key control points in pathways of de novo lipo-
genesis and lipid oxidation, as previously reported for leptin
(14). In addition, we also investigated the role of PI3K and




Intactmuscleswere obtained from 7- to 8-wk-oldmale BALB/cByJIco
mice (Charles River Laboratories, L’Arbresle, France). Before the start of
each experiment, the mice were adapted for at least 1 wk to a temper-
ature-controlled room (22 C) with a 12-h light, 12-h dark cycle. They had
free access to tap water and were maintained on a commercial pelleted
laboratory diet (Provimi-Lacta, Cossonay, Switzerland) consisting, by
energy, of 24% protein, 66% carbohydrates, and 10% fat. All animals
used in the present studies were maintained in accordance with our
institute’s regulations and guide for the care and use of laboratory
animals.
Muscle tissue preparations
For ex vivo calorimetric measurements, soleus and/or extensor digi-
torum longus (EDL)muscles were carefully dissected out intact together
with their tendons and freed of loosely attached connective tissue. They
were then placed on a stainless steel frame, at physiological resting
length, in the test chambers of a twin indirect microcalorimeters peri-
fused with Krebs-Ringer bicarbonate buffer at 30 C, as described pre-
viously (13).
Measurement of tissue respiration rate
The respiratory rate (MO2) of skeletal muscle wasmeasured for about
7 h by a method involving repeated O2 uptake determinations in our
twin microcalorimeter chambers as described by Barde et al. (22). The O2
partial pressure of a bubble-free liquid phase enclosed in a thick-walled
Lucite chamber was measured by a Clark O2 electrode connected to a
polarographic circuit, whose output voltage is directly proportional to
O2 partial pressure. At about 10-min intervals, a peristaltic pump par-
tially exchanged the solution for a fresh one within 2–3 min. All values
for MO2 were taken during steady-state respiration. The basal steady-
state MO2 was taken as the average value between 120 and 150 min after
placing the muscle preparations in the experimental chambers. For each
hormone, receptor antagonist or inhibitor that was subsequently added,
the steady-state respiration value was taken as the average value be-
tween 90 and 120 min after its administration. The choice of an effective
concentration for CRH antagonists or inhibitors was based upon pre-
liminary calorimetric experiments that involved testing several concen-
trations of each antagonist or inhibitor on muscle MO2. Because of the
long duration (2–2.5 h) necessary for assessing each steady-state MO2
value, only three steady-state MO2 values, i.e. the basal MO2 value and
sequential effects of only two concentrations of antagonists or inhibi-
tors—could be monitored in any given intact skeletal muscle on a given
day. The selected concentration for CRH receptor antagonists corre-
sponded to the lowest concentration tested that was effective in inhib-
iting CRH’s stimulatory effect on MO2, but which, in its own rights, did
not have an inhibitory effect on basalMO2; this corresponded to 1g/ml
for each of the twoCRH receptor antagonists used: antisauvagine-30 and
astressin. Furthermore, in testing whether CRH stimulates thermogen-
esis by the same mechanism (substrate cycling) that we previously
proposed for leptin (14), we used the same concentration of the various
inhibitors that we previously found to completely block the direct effect
of leptin on muscle thermogenesis (13, 14). We believe that these con-
centrations are close to the minimal effective dose in our assay because
concentrations corresponding to five times higher dilution of each in-
hibitor failed to produce statistically significant effects on CRH-induced
increases in muscle MO2.
AMPK/ACC phosphorylation and PI3K/Akt assays
Soleus muscles were incubated ex vivo in Krebs-Ringer buffer alone
for 30min, followed by incubation alone or in presence of a test hormone
or drug for 15 min, and then immediately frozen in liquid nitrogen.
Frozen muscles were homogenized and incubated in lysis buffer [20 mm
Tris-HCl, 138mmNaCl, 2.7mmKCl, 5% (vol/vol) glycerol, Nonidet P-40
and protease/phosphatase inhibitors] for 15min. After centrifugation at
13,000 rpm for 15 min, protein concentration was quantified and the
protein extracts were used for measurement of AMPK Thr172, ACC
Ser79, and protein kinase B/Akt (referred to as Akt) Ser473 phosphor-
ylation, or PI3K activity. For AMPK phosphorylation, 200 g of protein
extract were immunoprecipitated with phospho-AMPK (Thr172) or
phosphor-ACC (Ser 79) polyclonal antibodies (Cell Signaling, Beverly,
MA). The samples were then separated on a 10% SDS-PAGE gel and
blotted on a polyvinylidene difluoride membrane that was analyzed
with same phospho-AMPK (Thr172) or phosphor-ACC (Ser 79) poly-
clonal antibodies. For PI3K assay, 200 g of protein extract were im-
munoprecipitated either with phosphotyrosine (PY) monoclonal anti-
body (Cell Signaling), with antipan p85 rabbit polyclonal antibody
(obtained from M. P. Wymann’s laboratory), insulin receptor substrate
(IRS) 1 (Cell Signaling) or IRS2 (Upstate Biotechnology, Lake Placid, NY)
polyclonal antibody. The kinase reaction, thin-layer chromatography
separation, and signal detection were performed as previously de-
scribed by Pirola et al. (23). For Akt phosphorylation, the protein extract
was analyzed by immunoblot using Akt P-Ser 473-specific antibody
(Cell Signaling), the membrane was then stripped from the Akt P-Ser
473-specific antibody and treated with Akt antibodies (Cell Signaling).
Chemicals and drugs
All chemicals were purchased from Fluka (Buchs, Switzerland). Hu-
man CRH was synthesized by Bachem (Torrance, CA), and purity was
confirmed by HPLC. The peptide, as the acetate salts, was reconstituted
to a final concentration of 0.5 mg/ml (free base) in 0.9% saline acidified
with glacial acetic acid. The peptides were aliquoted and frozen at 70
C until the day of use. Stresscopin-related peptide (human) or urocortin
2was purchased fromBachem (Merseyside, UK), whereas Astressin and
antisauvagine-30 were purchased from Polypeptide Laboratories Inc.
(Torrance, CA), purity confirmed by HPLC, and the products supplied
as acetate salts. Wortmannin and hydroxy-citrate from Calbiochem (Lu-
zern, Switzerland), cerulenin from Fluka, and LY294002 as well as ad-
enine 9--d-arabinofuranoside (araA) from Sigma (St. Louis, MO). Eto-
moxir was a generous gift from Dr. W. Langhans (Zurich, Switzerland).
Statistics
The analysis of data on changes inMO2 in response to CRH and other
drugswas performed either by paired t test or byANOVAwith repeated
measures, using the statistical software STATISTIK (St. Paul,MN). Upon
detection of significant increases by ANOVA, post hoc pairwise com-
parisons were conducted using Scheffe´’s test, with the level of statistical
significance taken as P  0.05.
Results
Direct effect of CRH on skeletal muscle thermogenesis
The addition of CRH, at 0.1 or 0.5 g/ml, to the intact
skeletalmuscle preparations, resulted in significant increases











and 25% (P  0.01), respectively (Fig. 1A); at higher concen-
trations (1 g/ml), the addition of CRH did not lead to
further increase in MO2 (data not shown). A stimulatory
effect of CRH on MO2 is also observed in EDL muscles from
these same mice, but this increase (7% above basal values,
P 0.05) is much less pronounced than in the soleus muscle
(Soleus vs. EDL response, P 0.01). Real-time PCR data from
our laboratory indicate that this muscle type difference in
MO2 response cannot be attributed to differential gene ex-
pression of CRH-R2 because the mRNA levels were similar
in both soleus and EDL muscles. Because the CRH effect on
MO2 in EDL is small, subsequent studies were performed
only in the soleus muscle whose response to CRH is quan-
titatively more important. To test whether the observed di-
rect effect of CRH on muscle thermogenesis was due to
binding of CRH to CRH-R2 receptors (the only CRH re-
ceptor isoform so far reported to be expressed in skeletal
muscle), we investigated whether the CRH-induced increase
in soleus muscle MO2 could be prevented by the presence of
antisauvagine-30, a selective CRH-R2 antagonist, and
whether it could be mimicked by urocortin 2, a selective
CRH-R2 agonist. The results, presented in Fig. 1, B and C,
indicate that urocortin 2 also stimulates muscle MO2 (14%
above basal values, P  0.001) maximally at 0.25 g/ml; at
lower doses tested in preliminary studies (data not shown),
urocortin 2 had either no effect relative to basal MO2 at 0.05
g/ml or increased muscle MO2 by about 10–12% (P 0.05)
at 0.1g/ml. Antisauvagine-30, at concentrations that do not
have an effect on basal MO2 (Fig. 1D), resulted in a partial
inhibition of the stimulatory effect of CRH or urocortin 2 on
muscle MO2 (P  0.05), and its withdrawal resulted in an
increase in muscle MO2 (P 0.01) in response to continuous
administration of CRH or urocortin 2 (Fig. 1, B and C). How-
ever, complete blunting of the thermogenic effect of CRHand
urocortin 2 can be observed in presence of the nonselective
CRH receptor antagonist, astressin, at concentrations that do
no have an effect on basal MO2 (Fig. 1D). Indeed, as also
shown in Fig. 1, B and C, CRH (or urocortin 2) failed to
FIG. 1. Steady-state MO2 of: A, soleus and EDL muscles in
the basal state and during sequential addition of 0.1 or 0.5
g/ml of CRH; B, soleus muscles in presence or absence of
CRH, antisauvagine-30 (a selective CRH-R2 antagonist) or
astressin (a nonselective CRH receptor antagonist); C, so-
leus muscles in presence or absence of urocortin 2 (a
CRH-R2 agonist), antisauvagine-30 or astressin; and D,
soleus muscle indicating that at the concentrations used,
the CRH receptor antagonists (antisauvagine-30 and as-
tressin) did not alter basalMO2. All data are onMO2means,
with vertical bars representing SEs (n  5–7). Significant
effects in sequential changes in MO2 were assessed by
paired t test or by ANOVAwith repeatedmeasures followed
by Scheffe´’s test for pair-wise comparisons; in the latter
case, the values not sharing the same superscript letters











stimulatemuscleMO2 in the presence of astressin, in contrast
to that observed in contralateral muscles treated only with
CRH (or urocortin 2) (P 0.001). Taken together, these stud-
ies indicate that CRH can directly stimulate thermogenesis in
skeletal muscle, and that the thermogenic effects of CRH are
consequential to the activation of specific CRH receptors.
Requirement for lipid oxidation and de novo lipogenesis
We have previously proposed that substrate cycling be-
tween de novo lipogenesis and lipid oxidation, a futile cycle
known to be involved in brown adipose tissue thermogenesis
(24), also operate as a thermogenic effector in skeletal muscle
(15) on the basis of previously reported calorimetric studies
indicating that inhibition of key control points along path-
ways in this substrate cycle resulted in the blunting of the
direct effect of leptin in stimulating thermogenesis in skeletal
muscle (14). After our findings above that CRH also stimu-
lates skeletal muscle thermogenesis with a similar muscle
type specificity (soleus  EDL) and similar magnitude (20%
increase in soleus muscle) as previously reported for leptin
(13, 14), we test here whether CRH might also operate
through the same molecular mechanisms of substrate cy-
cling. To this end, we used the same concentrations of in-
hibitors that we previously used to implicate a potential role
of this substrate cycle in the direct effect of leptin on muscle
thermogenesis (14).
The results presented in Fig. 2A show that the direct effect
of CRH on muscle MO2 is completely inhibited (P  0.001)
by 1) etomoxir, a known selective inhibitor of carnitine
palmitoyl transferase-1 (CPT-1), which regulates the entry of
long chain fatty acids into mitochondria, and by 2) the re-
placement of glucose in the perifusion medium with 2-de-
oxyglucose, a glucose analog whose metabolism stops after
its phosphorylation by hexokinase, thereby indicating that
CRH-induced thermogenesis in muscle requires both fatty
acid oxidation and glucose metabolism. A requirement of de
novo lipogenesis for CRH-induced thermogenesis in skeletal
muscle is suggested by data in Fig. 2B, showing that CRH-
induced increases in muscle MO2 are completely abolished
(P  0.01) by the addition of inhibitors of key control points
in pathways leading to the synthesis of lipids, namely by
either OH-citrate, which inhibits the enzyme citrate lyase, or
by cerulenin, an inhibitor of fatty acid synthase. Taken to-
gether, these data suggest that lipid oxidation, glucose me-
tabolism and de novo lipogenesis are all required for the direct
thermogenic effect of CRH in skeletal muscle.
Requirements for PI3K and AMPK
We have also previously proposed that PI3K and AMPK
are key signaling pathways required for the orchestration of
this thermogenic substrate cycle between de novo lipogenesis
and lipid oxidation in response to leptin (14, 15). To test
whether PI3K and AMPK signaling are also involved in the
direct thermogenic effects of CRH in skeletal muscle, we
investigated here whether the increase in muscle MO2 in
response to CRH might be abolished by inhibitors of PI3K or
AMPK, at concentrations previously reported to be effective
in blocking the thermogenic effect of leptin (13, 14). Further-
more, we also measured, using biochemical assays for PI3K
and AMPK, whether these signaling pathways are stimu-
lated in skeletal muscle incubated with CRH. The results,
presented in Fig. 3A, show that the subsequent addition of
either wortmannin or LY294002, two specific inhibitors of
PI3K, completely abolished the CRH-induced increase in
soleus MO2 (P  0.001 for wortmannin and P  0.05 for
LY294002). Using in vitro kinase assays in ex vivo intact soleus
muscles incubated with CRH, insulin, or saline solution as
control, we could not, however, detect an induction of PY,
IRS1, IRS2 and p85-associated PI3K activity, nor in Akt phos-
phorylation (a target of the PI3K pathway) with 0.1 g/ml
CRH (Fig. 3, B and C) nor with 0.5 g/ml CRH (data not
shown); this is in contrast to the expected marked increases
in both PI3K and Akt signaling observed in response to
insulin (Fig. 3, B and C). These data from biochemical assays,
together with those obtained by calorimetry with the use of
PI3K inhibitors, suggest that at least a basal PI3K activity is
required (and possibly sufficient) for the thermogenic effect
of CRH.
FIG. 2. Steady-state MO2 of soleus muscle (A) in
the basal state, followed by sequential addition of
CRH and etomoxir (an inhibitor of fatty acid oxi-
dation), or during addition of CRH, and subse-
quently after addition of CRH in buffer in which
glucose has been replaced by 2-deoxyglucose
(2-DG), and (B) MO2 in the basal state, during se-
quential addition of CRH and OH-citrate, an inhib-
itor of citrate lyase, or during sequential addition of
CRH and cerulenin, an inhibitor of fatty acid syn-
thase. Note that at the concentrations used, the
inhibitors did not alter basal MO2. All data are
means, with vertical bars representing SEs (n 
5–6). Statistical significance of differences are











A requirement for AMPK signaling is also indicated by
data presented in Fig. 3D showing that prior addition of
adenine araA, an intracellular competitive inhibitor of
AMPK, prevents CRH-induced increases in muscle MO2,
and that both AMPK and ACC phosphorylation are in-
creased after treatment of skeletal muscle with CRH (Fig. 3,
E and F), these increases beingmarginalwith 0.1g/mlCRH
(20%; not significant), but significant with 0.5 g/ml CRH
(40–120%, P  0.01). Taken together, these data suggest
that both PI3K and AMPK activities are required for the
direct action of CRH in stimulating skeletal muscle
thermogenesis.
Discussion
We show here, for the first time, that CRH can directly
stimulate thermogenesis in skeletal muscle, an effect that is
muchmore pronounced in oxidativemuscles (soleus) than in
glycolyticmuscles (EDL). This thermogenic response to CRH
in skeletal muscle could be completely blocked by the non-
selective CRH receptor antagonist astressin, thereby show-
ing that this response is dependent upon the activation of
specific CRH receptors. To date, only one CRH receptor
isoform, CRH-R2, has been described in skeletalmuscle (19,
20). Our data showing that the thermogenic effect of CRHcan
be mimicked by urocortin 2 (a CRH-R agonist with high
affinity for CRH-R2), and that it can be partially inhibited by
antisauvagine-30 (a selective CRH-R2 antagonist), are con-
sistent with a role for CRH-R2 in the peripheral effect of CRH
on muscle thermogenesis. At present, we cannot rule out
whether the partial inhibitory effects of antisauvagine-30 on
thermogenic actions of CRH or that of urocortin 2 are due to
a partial inhibition of CRH-R2 or because skeletal muscle
FIG. 3. A, Steady-state MO2 of soleus muscles in the basal state, during sequential addition of CRH and wortmannin or LY294002 (inhibitors
of PI3K); note that at the concentrations used, these inhibitors have no effect on basal MO2; B, immunoprecipitate (IP) of PY, IRS1, IRS2, and
p85 associated with PI3K activity from soleus muscles in response to CRH or to insulin as a positive control; C, Immunoblot showing Akt
phosphorylation from soleus muscle in response to CRH or to insulin as a positive control; D, steady-state MO2 of soleus muscles in the basal
state, during the sequential addition of araA (a competitive inhibitor of AMPK) and CRH or the response of controlateral muscles to CRH in
absence of araA; and E, Western blot showing that AMPK phosphorylation is increased marginally in soleus muscles incubated with 0.1 g/ml
CRH, but by about 2-fold in soleus muscles incubated with either 0.5 g/ml CRH or 10 mM of 5-aminoimidazole-4-carboxamide ribonucleoside
(a well-known activator of AMPK) as a positive control; F, Western blots showing that ACC phosphorylation is also increased in response to
CRH. For the calorimetry data, all data aremeans, with vertical bars representing SEs (n 5–6); statistical significance of differences are shown
as indicated in the legend to Fig. 1. For the PI3K, Akt, AMPK, andACC assays, the effect of each hormone or drugwas investigated by comparing
pools of four left leg soleus muscles (hormone or drug treated) and four right leg soleus muscles (mock controls) from the same animals, and











expresses other CRH receptor isoforms that are not yet iden-
tified. This latter explanation might assume greater impor-
tance after the observation, by immunohistochemistry anal-
ysis of both oxidative and glycolytic skeletalmuscles, that the
CRH-R2 protein could be localized in neural structures,
blood vessels, myotendinous junctions, and endomysial/
perimysial spaces, but not in myocytes (25). On the other
hand, the report that CRH-R2 expression is detectable in
primary cardiomyocytes cell culture by RT-PCR suggests
that this receptor subtype is also expressed in muscle cells
(26). Taken together, these observations raise questions as to
whether the differential thermogenic responses to CRH ob-
served here in mouse soleus and EDL muscles (which we
found to show similar gene expressions levels of CRH-R2)
would reside 1) in the abundance of this putative unidenti-
fied CRH receptor isoform in myocytes, 2) in the relative
abundance of CRH-R2 in different tissues/structures
within the muscle, or 3) in events downstream to CRH-R2
signaling. Furthermore, because the heart, like skeletal mus-
cle, also expresses CRH-R2 and urocortin 2 (27), the ques-
tions arise as to whether the localization of CRH-R2 recep-
tors in the heart muscle is fundamentally different from that
in skeletal muscle, and whether urocortin 2—a potentially
important ligand to the CRH-R2 in both muscles—plays an
autocrine/paracrine role in controlling substratemetabolism
and thermogenesis in these tissues.
Despite considerable search over the past decades for ef-
fectors of thermogenesis in skeletal muscle, there is to date
no convincing evidence that this tissue is a site of regulated
mitochondrial uncoupling, by analogy to that mediated by
the uncoupling protein (UCP1) in brown adipose tissue. In
fact, the notion that the uncoupling protein homologs, UCP3
and UCP2, could be physiological regulators of thermogenic
uncoupling in skeletal muscle has not received experimental
support despite considerable testing (28). This point is fur-
ther illustrated by the recent demonstration that constitutive
UCP3 overexpression at physiological levels in mouse skel-
etal muscle, while increasing the capacity of this tissue for
fatty acid oxidation, nonetheless failed to increase thermo-
genesis (29). Given doubts that regulated mitochondrial un-
coupling underlies thermogenesis in intact muscle, there is
nowadays renewed interest about the potential role of futile
cycles toward understanding the biochemical basis of ther-
mogenesis in general and in skeletal muscle thermogenesis
in particular. In this context, an increased rate of substrate
cycling between triacylglycerol and fatty acid has recently
been shown to account for about 15% of the thermogenic
effect of leptin administered in vivo (30), and we have pre-
viously reported that leptin can directly stimulate thermo-
genesis in oxidative muscle ex vivo (13) possibly by promot-
ing an energy dissipating substrate cycling between de novo
lipogenesis and lipid oxidation (14, 15)—a futile cycle that is
also known to be involved in cold-induced thermogenesis in
brown adipose tissue (15, 24). We present here data indicat-
ing that the direct effect of CRH on skeletal muscle thermo-
genesis is also dependent upon this flux of substrates be-
tween de novo lipogenesis and fatty acid oxidation because
the increase in muscle O2 consumption in response to CRH
is completely inhibited by interference with either 1) the
metabolism of glucose, using 2-deoxyglucose; 2) the conver-
sion of citrate to acetyl-CoA, using the citrate lyase inhibitor
hydroxycitrate; 3) the conversion of malonyl-CoA to fatty
acids, using cerulenin, an inhibitor of fatty-acid synthase; or
with 4) the entry of fatty acids intomitochondrial-oxidation
pathwayusing etomoxir, an inhibitor of CPT-1. It is proposed
that during CRH-induced activation of this substrate cycle
(depicted in Fig. 4), acetyl-CoA produced from fatty acid and
glucose oxidation, will overload the Krebs cycle. This will
result in excess mitochondrial citrate that, in the cytoplasm,
will exert an allosteric activation of the enzyme ACC and at
the same time, under the action of citrate lyase, will provide
acetyl-CoA to ACC for the synthesis of malonyl-CoA. The
latter will serve as the main substrate for fatty acid synthase,
thereby producing a new pool of fatty acids. Glucose plays
a central role in this cycle as a source of Krebs cycle inter-
mediates and reduced nicotinamide adenine dinucleotide
phosphate molecules that are required for de novo synthesis
of fatty acids (31). The capacity of skeletal muscle to perform
de novo lipogenesis is strongly supported by the recent dem-
onstrations in muscle satellite cells that glucose stimulates
the expression of sterol regulatory element binding pro-
tein-1c mRNA as well as key genes encoding glycolytic and
lipogenic enzymes, leading to an increased lipogenic flux
and intracellular lipid accumulation (32, 33). These findings
in primary muscle cell cultures provide direct evidence that
de novo lipogenesis can occur in rat and human skeletal mus-
cle cells and are consistent with data of metabolic labeling
fromour laboratory showing that de novo lipogenesis can also
occur in intact mouse soleus and EDL muscles used in our
calorimetric studies (14, 15).
Our data also suggest that this CRH-induced substrate
cycling between de novo fatty acid synthesis and fatty acid
oxidation in skeletal muscle is coordinated by AMPK and
PI3K signaling because 1) the thermogenic effect of CRH in
the soleus muscle, which is associated with AMPK and ACC
phosphorylation, can be prevented by pharmacological in-
hibition of AMPK activation using araA, and because 2) the
effects of CRH on muscle thermogenesis can also be com-
pletely inhibited by inhibitors of PI3K (wortmannin or
LY294002). Because our data also indicate that the require-
ment for PI3K activity in CRH-mediated thermogenesis in
skeletal muscle is independent of a CRH-mediated induction
of PI3K activity, it is possible that basal levels of PI3K activity
(inhibited by wortmannin or LY294002) are required to sup-
port the direct thermogenic effect of CRH in skeletal muscle.
Further evidence underscoring a dual requirement for
AMPK and PI3K signaling in the operation of this substrate
cycling can be derived from our previous findings (14) that
the administration of insulin (a potent stimulator of PI3K
activity) to ourmuscle preparations is not sufficient to induce
skeletal muscle thermogenesis, and that the activation of
AMPK by 5-aminoimidazole-4-carboxamide ribonucleoside
(or by leptin) led to an increase in muscle thermogenesis that
is abolished by the PI3K inhibitor wortmannin (14). Thus, as
depicted in Fig. 4, in response to CRH, AMPK-induced phos-
phorylation of ACC, will counterbalance the stimulatory ac-
tion of citrate on ACC thereby resulting in reduced malonyl-
CoA concentration, disinhibition of CPT-1, and increased











of acetyl-CoA that will fuel the Krebs cycle and increase
citrate levels. Conversely, PI3K activity will promote cellular
glucose uptake and synthesis of fatty acids. Thiswould occur
despiteAMPK-induced reduction inmalonyl-CoAbecause it
is known that full phosphorylation of ACC by AMPK results
in an inhibition of ACC activities only by 50–60% (34, 35).
Such partial inhibition of ACC is expected to redirect the flux
of acetyl-CoA and malonyl-CoA toward fatty acid oxidation
but would still allow substantial rate of fatty acid synthesis,
particularly in presence of high levels of citrate. According
to the stoichiometry of this substrate cycle, the synthesis of
one molecule of palmitic acid from acetyl-CoA and its reoxi-
dation to acetyl-CoAwould cost at least 14molecules of ATP.
Repeated recycling of acetyl-CoA through the flux of sub-
strates across lipogenesis followed by -oxidation could
therefore constitute the mechanism by which CRH directly
stimulates thermogenesis in skeletal muscle. The increases in
thermogenesis observed here with CRH are quite similar to
those observed with leptin, namely between 20 and 30% (13,
14), and higher than we observe with catecholamines (about
5–15% increase; Seydoux, J., and A. G. Dulloo, unpublished
data). It should, however, be emphasized that because the
skeletal mass is large (contributing between 30 and 40% of
total body mass and an even greater percentage of daily
energy expenditure), a relatively small increase in muscle
respiration rate can have a significant impact on whole body
energy expenditure and on muscle lipid homeostasis. Con-
sequently, the substrate cycling proposed here in response to
CRH could also underscore a thermogenic effector system
through which mobilization of the im triglycerides stores
might have contributed to the increase inwhole-body energy
expenditure and fat oxidation observed in humans infused
with CRH (21).
In conclusion, this study demonstrates that CRH can di-
rectly stimulate thermogenesis in skeletal muscle and pro-
vides evidence that raises the possibility that the direct action
of CRH might be mediated by substrate cycling between de
novo lipogenesis and lipid oxidation, orchestrated by PI3K
and AMPK signaling. The capacity of CRH to directly stim-
ulate metabolic rate by an energy dissipating substrate cycle
linking glucose and lipid metabolism to thermogenesis in
skeletal muscle provide the rationale for the development of
peripheral CRH receptor agonists as potential thermogenic
drugs in the management of obesity or against excessive
accumulation of intramyocellular lipids, and hence against
skeletal muscle lipotoxicity and insulin resistance.
FIG. 4. Model illustrating an energy-dissipat-
ing futile substrate cycling between de novo
lipogenesis and lipid oxidation in response to
CRH, orchestrated by PI3K and AMPK sig-
naling, in skeletal muscle (see text for details).
TG, Triglycerides. The proposed model of sub-
strate cycling in response to CRH rests upon
data from calorimetric studies showing that
the direct effect of CRH on skeletal muscle
thermogenesis is inhibited by pharmacological
interference at any one of key control points in
the flux of substrates denoted by symbol (X),
namely: 1) with glucose metabolism using
2-deoxyglucose (2-DG); 2) with the conversion
of citrate to acetyl-CoA using hydroxy-citrate,
an inhibitor of citrate lyase; 3) with the con-
version of malonyl-CoA to fatty acids using
cerulenin, an inhibitor of fatty acid synthase;
and 4) with the entry of fatty acid into mito-
chondrial -oxidation pathway using eto-
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